Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Basal Cell 4Recurrence 3Basal Cell Nevus Syndrome 3Skin Neoplasms 2Multiple Myeloma 2Medulloblastoma 2Thrombocytosis 1Thrombocythemia, Essential 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Diseases 1Neuroblastoma 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Neoplasms 1Hematologic Diseases 1Glioma 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1Astrocytoma 1

Interventions

Gemcitabine 5130-nm albumin-bound paclitaxel 5Albumin-Bound Paclitaxel 4sonidegib 1napabucasin 1Piperacillin, Tazobactam Drug Combination 1Paclitaxel 1Irinotecan 1HhAntag691 1Duodenoscopes 1Cisplatin 1Cefoxitin 1Capecitabine 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pancreatic Diseases × sonidegib × Clear all
NCT01431794 2020-01-22

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Terminated
23 enrolled 10 charts
Gastrointestinal

Carcinoma, Pancreatic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡